Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03505554
Title A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma (CRU3)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Milano Bicocca
Indications

lymphoma

Therapies

Lorlatinib

Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST